JPRN-jRCT2011260002 Ramantamig Refractory Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines JPRN-jRCT2011260002 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 13 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why JPRN-jRCT2011260002 is a hot trial to watch
Refractory Multiple Myeloma is being segmented by mechanism, treatment setting, geography and endpoint architecture. JPRN-jRCT2011260002 is notable because it evaluates Ramantamig in a Phase 3 design sponsored by Janssen Pharmaceuticals, Inc.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | JPRN-jRCT2011260002 |
| Official title | A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlogy-5) |
| Phase / status | Phase 3 / 募集前 |
| Intervention | Ramantamig |
| Sponsor | Janssen Pharmaceuticals, Inc. |
| Geography | Taiwan Province, Czechia, Italy, Turkey, Greece, South Korea, Germany, Poland, China, Brazil, France, Canada, Australia, Israel, India, Japan, United States, Spain |
| Enrollment | [object Object] |
| Primary endpoint | 1. Complete Response (CR) or Better CR or better is defined as the percentage of participants achieving CR or stringent complete response (sCR) prior to subsequent antimyeloma therapy in accordance with the international myeloma working group (IMWG) criteria during or after the study treatment. [Time Frame: Up to approximately 41 months] 2. Progression-Free Survival (PFS) PFS is defined as the duration from the date of randomization to either progressive disease (PD) or death, whichever comes first. Disease progression will be determined according to the IMWG response criteria. [Time Frame: Up to approximately 41 months] |
| Endpoint time frame | Not reported |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
The indexed record describes a Phase 3 study of Ramantamig in Refractory Multiple Myeloma.
Allocation is Randomized, masking is Open Label, and the intervention model is Parallel Assignment. Planned enrollment of [object Object] participants across Taiwan Province, Czechia, Italy, Turkey, Greece, South Korea, Germany, Poland, China, Brazil, France, Canada, Australia, Israel, India, Japan, United States, Spain shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- 1. Complete Response (CR) or Better CR or better is defined as the percentage of participants achieving CR or stringent complete response (sCR) prior to subsequent antimyeloma therapy in accordance with the international myeloma working group (IMWG) criteria during or after the study treatment. [Time Frame: Up to approximately 41 months] 2. Progression-Free Survival (PFS) PFS is defined as the duration from the date of randomization to either progressive disease (PD) or death, whichever comes first. Disease progression will be determined according to the IMWG response criteria. [Time Frame: Up to approximately 41 months] (time frame not reported)
- 1. 完全奏効（CR）以上 CR以上とは、試験治療中又は試験治療後に国際骨髄腫作業部会（IMWG）基準に従って、後続の抗骨髄腫治療開始前までにCR又は厳格な完全奏効（sCR）を達成した参加者の割合として定義する。 評価期間：最長約41か月 2. 無増悪生存期間（PFS） PFSとは、ランダム化日から、病勢進行（PD）又は死亡のいずれか早い方までの期間として定義する。病勢進行はIMWGの奏効判定基準に従い判定する。 評価期間：最長約41か月 (time frame not reported)
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Ramantamig is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Janssen Pharmaceuticals, Inc. is resolved to a normalized organization record in HUNTERDON COUNTY, United States. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
JPRN-jRCT2011260002 provides a focused lens on Refractory Multiple Myeloma development. Its value will be determined by whether Ramantamig can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
